Independent associations of MGMT promoter methylation and TERT promoter mutation with overall survival in glioblastoma: a single-center retrospective cohort study.
Summary
This single-center retrospective study investigated the prognostic impact of MGMT promoter methylation and TERT promoter mutations in 54 patients with WHO grade 4 glioblastoma. The findings indicate that MGMT methylation is independently associated with improved overall survival, whereas TERT mutations predict worse survival. Adjuvant chemoradiotherapy was also confirmed to improve outcomes. A combined stratification using both biomarkers allows for the identification of four distinct prognostic subgroups, with MGMT-methylated/TERT-wild-type patients exhibiting the longest survival.
Analysis
Clinique : This retrospective cohort study provides real-world evidence for the independent prognostic value of MGMT methylation and TERT mutations in WHO grade 4 glioblastoma. The combined assessment of these two biomarkers enables a four-tier risk stratification, which could refine patient management and counseling. Although retrospective, the study suggests that routine combined MGMT/TERT evaluation for prognostic assessment should be considered, potentially impacting practice within 3-5 years. Biomol : MGMT promoter methylation was assessed using methylation-specific PCR, and TERT promoter mutations (C228T/C250T) were detected via Sanger sequencing, both established molecular techniques. The finding of their independent and combined prognostic value reinforces their role as key biomarkers. These analyses are performed on tumor samples and are robust for clinical application.